Genmab achieves first milestone in Roche antibody collaboration  

Genmab has achieved the first milestone in its collaboration with Roche

Genmab A/S has announced that it has achieved the first milestone in its collaboration with pharma giant Roche, as a human antibody generated by Genmab has effectively reached proof of concept in an animal disease model. Genmab is utilizing its antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Under the current agreement, Genmab will receive milestone as well as royalty payments on successful products. If all goals are reached, the value of the collaboration to Genmab could be as high as USD 100 million plus royalties.


An offshoot of the US company Medarex, Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and plans to assemble a broad portfolio of new therapeutic products arising from research into the human genome. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, The Netherlands and Princeton, New Jersey, US.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×